177 related articles for article (PubMed ID: 35696453)
1. Computational discovery of small drug-like compounds as potential inhibitors of PD-1/PD-L1 interactions.
Urban VA; Davidovskii AI; Veresov VG
J Biomol Struct Dyn; 2023 Jul; 41(11):5345-5361. PubMed ID: 35696453
[TBL] [Abstract][Full Text] [Related]
2. Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein.
Waqas M; Halim SA; Alsalman A; Khan A; Elkord E; Al-Harrasi A
J Biomol Struct Dyn; 2023; 41(24):14771-14785. PubMed ID: 36927289
[TBL] [Abstract][Full Text] [Related]
3. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.
Guzik K; Tomala M; Muszak D; Konieczny M; Hec A; Błaszkiewicz U; Pustuła M; Butera R; Dömling A; Holak TA
Molecules; 2019 May; 24(11):. PubMed ID: 31151293
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.
Zhu P; Zhang J; Yang Y; Wang L; Zhou J; Zhang H
Mol Divers; 2022 Feb; 26(1):245-264. PubMed ID: 33786726
[TBL] [Abstract][Full Text] [Related]
5. SAR study of small molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction.
Kawashita S; Aoyagi K; Fukushima K; Hantani R; Naruoka S; Tanimoto A; Hori Y; Toyonaga Y; Yamanaka H; Miyazaki S; Hantani Y
Chem Biol Drug Des; 2021 Nov; 98(5):914-929. PubMed ID: 34495575
[TBL] [Abstract][Full Text] [Related]
6. Computational design of PD-L1 small molecule inhibitors for cancer therapy.
Chandrasekaran J; Elumalai S; Murugesan V; Kunjiappan S; Pavadai P; Theivendren P
Mol Divers; 2023 Aug; 27(4):1633-1644. PubMed ID: 36006501
[TBL] [Abstract][Full Text] [Related]
7. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
8. Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach.
Mittal L; Tonk RK; Awasthi A; Asthana S
Arch Biochem Biophys; 2021 Nov; 713():109059. PubMed ID: 34673001
[TBL] [Abstract][Full Text] [Related]
9. Insights into small molecule inhibitor bindings to PD-L1 with residue-specific binding free energy calculation.
Xia W; He L; Bao J; Qi Y; Zhang JZH
J Biomol Struct Dyn; 2022; 40(22):12277-12285. PubMed ID: 34486939
[TBL] [Abstract][Full Text] [Related]
10. Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.
Gao Y; Wang H; Shen L; Xu H; Deng M; Cheng M; Wang J
Bioorg Chem; 2022 Jun; 123():105769. PubMed ID: 35405572
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
[TBL] [Abstract][Full Text] [Related]
12. Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction.
Sasmal P; Kumar Babasahib S; Prashantha Kumar BR; Manjunathaiah Raghavendra N
Bioorg Med Chem; 2022 Nov; 73():117001. PubMed ID: 36126447
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism of Food-Derived Polyphenols on PD-L1 Dimerization: A Molecular Dynamics Simulation Study.
Guo Y; Liang J; Liu B; Jin Y
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681584
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
15. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
[TBL] [Abstract][Full Text] [Related]
16. Virtual Screening and In Vitro Evaluation of PD-1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products.
Lung J; Hung MS; Lin YC; Hung CH; Chen CC; Lee KD; Tsai YH
Molecules; 2020 Nov; 25(22):. PubMed ID: 33202823
[TBL] [Abstract][Full Text] [Related]
17. Fragment-based screening of programmed death ligand 1 (PD-L1).
Perry E; Mills JJ; Zhao B; Wang F; Sun Q; Christov PP; Tarr JC; Rietz TA; Olejniczak ET; Lee T; Fesik S
Bioorg Med Chem Lett; 2019 Mar; 29(6):786-790. PubMed ID: 30728114
[TBL] [Abstract][Full Text] [Related]
18. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
20. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]